TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Constraint-induced Movement Therapy (CIMT) and Bimanual Training (HABIT) in Children With Hemiplegic Cerebral Palsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~willingness to agree to intervention and testing procedures and travel to the University for participation and testing.~Exclusion Criteria:~* health problems not associated with CP~* uncontrollable seizures~* visual problems that would interfere with carrying out the intervention or testing~* botulinum toxin therapy in the upper extremity musculature during the last six months or who wish to receive it within the period of study

- Gender: ALL
- Minimum Age: 30 Months
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- CIMT Intervention (Type: EXPERIMENTAL): Participants randomized to this arm were provided with 90 minutes of Constraint-Induced Movement Therapy (CIMT), which requires hand restraint and progression of unimanual tasks.
- HABIT Intervention (Type: EXPERIMENTAL): Participants randomized to this arm were provided with 90 minutes of Hand-Arm Bimanual Intensive Therapy (HABIT), which requires that tasks are progressed bimanually.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Diacerein on Glycemic Control and Liver Fat in Type 2 Diabetes Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes.~* Presence of liver steatosis diagnosed by ultrasound or transient elastography (Fibroscan®)~* Age 30-75 years.~* HbA1c 7.5- 9.5 for at least 8 weeks prior to screening.~* Stable diabetes therapeutic regimen consisting of either diet, oral hypoglycemic agents with or without insulin for 8 weeks prior to randomization.~Exclusion Criteria:~* Body mass index \> 40 kg/m2~* Serum creatinine ≥180mmol/L or estimated glomerular filtration rate \< 30 ml/min.~* Presence of any serious concomitant disease, such as a pulmonary disease or malignant disorders.~* Current daily alcohol ingestion ≥20 g.~* Hepatotoxic drugs.~* Presence of other chronic liver disease other than nonalcoholic fatty liver disease, including hepatitis B virus and hepatitis C virus infection, hemochromatosis, Wilson's disease, alfa-1 antitrypsin deficiency, autoimmune hepatitis.~* Women seeking pregnancy.~* Current use or previous use within 6 months of vitamin E or pioglitazone

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): All subjects will be given placebo identically matched with regard to shape, color and taste. They will be given one tablet/day for 2 weeks and then two tablets/day for the duration of sudy.
- Diacerein (Type: EXPERIMENTAL): All subjects will be given diacerein with a starting dose of 50 mg in one tablet once daily for 2 weeks. After 2 weeks, they will be given diacerein 50 mg in one tablet twice daily for the duration of sudy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed malignant advanced solid tumour refractory to standard therapy or for which no suitable effective standard therapy exists.~Exclusion Criteria:~* Anti-cancer therapy including chemotherapy, radiotherapy, endocrine therapy, immunotherapy or use of other investigational agents within the 4 weeks prior to trial entry (or a longer period depending on the defined characteristics of the agents used).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- KU-0059436 (Type: EXPERIMENTAL): KU-0059436 administered orally twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single Dose Ranging Study of BI 1744 CL (Olodaterol) in Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion criteria:~1. Diagnosis of chronic obstructive pulmonary disease~2. Smoking history of more than 10-pack years~Exclusion criteria:~1. History of asthma, allergic rhinitis, myocardial infarction or unstable of life-threatening cardiac arrhythmias~2. Marked baseline prolongation of QT/QTc interval

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- olodaterol 2 mcg (Type: EXPERIMENTAL): solution for inhalation
- olodaterol 5 mcg (Type: EXPERIMENTAL): solution for inhalation
- olodaterol 10 mcg (Type: EXPERIMENTAL): solution for inhalation
- olodaterol 20 mcg (Type: EXPERIMENTAL): solution for inhalation
- olodaterol 40 mcg (Type: EXPERIMENTAL): solution for inhalation
- placebo (Type: PLACEBO_COMPARATOR): solution for inhalation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of the ALK Grass Tablet in Subjects With Hayfever

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Eligibility Criteria:~* A history of grass pollen induced rhinoconjunctivitis~* Positive skin prick test to grass~* Positive specific IgE to grass

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Diabetic macular edema (DME) with central involvement in the study eye~* Best corrected visual acuity (BCVA) early treatment diabetic retinopathy study (ETDRS) letter score of 78 to 24 (approximate Snellen equivalent of 20/32 to 20/320) in the study eye with decreased vision determined to be primarily the result of DME~* Willing and able to comply with clinic visits and study-related procedures~* Provide informed consent signed by study participant or legally acceptable representative~Extension Phase: All randomized patients that complete visit 26, week 96, as long as the patient 1) provides informed consent and 2) no treatment for DME has been given in the study eye other than the randomized study treatment.~Key Exclusion Criteria:~* Evidence of macular edema due to any cause other than diabetes mellitus in either eye~* Active proliferative diabetic retinopathy in the study eye~* IVT anti-VEGF treatment (aflibercept, ranibizumab, bevacizumab, brolucizumab, pegaptanib sodium) or panretinal laser photocoagulation (PRP) /macular laser photocoagulation within 12 weeks (84 days) or intraocular or periocular corticosteroids within 16 weeks (112 days) of the screening visit in the study eye~* Prior IVT investigational agents in either eye (eg, anti-ang-2/anti-VEGF bispecific monoclonal antibodies, gene therapy, etc.) at any time~* Treatment with ocriplasmin (JETREA®) in the study eye at any time~NOTE: Other Protocol Defined Inclusion/Exclusion Criteria Apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- aflibercept Q8 (Type: ACTIVE_COMPARATOR): Administered every 8 weeks after a loading phase
- High-Dose aflibercept Q12 (Type: EXPERIMENTAL): Administered every 12 weeks after a loading phase
- High-Dose aflibercept Q16 (Type: EXPERIMENTAL): Administered every 16 weeks after a loading phase

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Therapy for Chronic Cold Agglutinin Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. CAD diagnosis defined by the combination of:~   * Chronic haemolysis~  * Cold agglutinin titre \> 64~  * Positive direct antiglobulin test when performed with polyspecific antiserum, negative (or only weakly positive) with anti-IgG, and strongly positive with anti-C3d~2. The presence of a clonal B-cell lymphoproliferative disorder defined by:~   * Monoclonal IgMκ band by serum electrophoresis and immunofixation, and~  * Lymphocyte phenotype with κ/λ-ratio \> 3.5 and CD20+,κ+ co-expression, using flowcytometric immunophenotyping of bone marrow aspirates~3. Clinical symptoms requiring treatment, such as anaemia or Raynaud-like symptoms~4. Informed consent~Exclusion Criteria:~1. An aggressive lymphoma~2. Blood lymphocyte count \> 50 . 109/L~3. Non-lymphatic malignant disease other than basal cell carcinoma~4. Contra-indications to rituximab or fludarabine therapy~5. Inability to cooperate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Different Sedation Regimes on Cognitive Function in Lower Gastrointestinal System Endoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients between 18-65 years of age (ASA I-III risk groups), scheduled for elective colonoscopy~Exclusion Criteria:~* Patient refusal~* Mini mental test (MMT) score\<26~* Amsterdam Preoperative Anxiety and Information Scale (APAIS ) score \>10~* Advanced cardiopulmonary or psychiatric disease~* Chronic alcohol abuse~* Morbid obesity~* Known allergy to study drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group MM (Type: OTHER): 2 mg midazolam and 20mg meperidine given intravenously and additional 1-2mg midazolam and 20mg meperidine (wtih a maximum total of 5 mg midazolam and 50 mg meperidine) given when FPS greater than 3
- Group RP (Type: OTHER): 100 mcg/kg/min propofol infusion and 1 mcg/kg remifentanil bolus administered and additional 0,5 mcg/kg remifentanil bolus given when FPS greater than 3

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Atorvastatin for Prevention of Postoperative Atrial Fibrillation After Off-Pump Coronary Artery Bypass Grafting Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* consecutive patients scheduled for the elective off-pump CABG surgery~Exclusion Criteria:~* prior statin use~* previous episodes of atrial fibrillation~* impaired renal function with serum creatinine \>2mg/dL~* serum aspartate aminotransferase or alanine aminotransferase concentrations more than 3 times the upper limit of normal~* a malignancy or inflammatory disease

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Atorvastatin group
- 2 (Type: NO_INTERVENTION): Control group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ethyl Chloride for NPWT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* an orthopaedic/trauma wound and/or surgical incision~* treatment with NPWT as a hospital inpatient~* minimum of at least one NPWT dressing changes or discontinuation of NPWT prior to discharge.~* dressing change in enterostomal therapy department~Exclusion Criteria:~* cognitive impairment preventing informed consent~* history of hypersensitivity to cold/vapocoolant~* outpatient NPWT

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Ethyl Chloride (Type: EXPERIMENTAL): Ethyl Chloride topical anesthetic mist will be sprayed on the area of adhesive during dressing change for patients with negative pressure wound therapy
- Tissue culture grade water (Type: PLACEBO_COMPARATOR): Tissue culture grade water (Nature's Tears Eyemist) will be sprayed on the area of adhesive during dressing change for patients with negative pressure wound therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Calcifediol Supplementation in Asthma Control in Asthmatic Patients With Vitamin D Deficiency (ACViD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Medical diagnosis of bronchial asthma~* serum 25(OH)D3 levels \< 30 ng/ml.~Exclusion Criteria:~* smoking habit ≥ 10 pack-years,~* taking vitamin D supplements,~* kidney disease (creat. \> 2 mg/dl),~* hypercalcaemia (corrected with proteins \> 10.5 mg/dl),~* repeat episodes of renal colic,~* any gastrointestinal disease that might interfere with vitamin D absorption,~* severe psychosocial problems,~* pregnant~* breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention Group (IG) (Type: EXPERIMENTAL): Calcifediol (Hidroferol®) in 16,000-IU ampoules taken weekly by the oral route
- Control Group (CG) (Type: PLACEBO_COMPARATOR): Placebo in a presentation with an identical appearance taken weekly by the oral route

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Impact of Zinc Supplementation on Left Ventricular Function in Nonischemic Cardiomyopathy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects (n=40) ≥21 years of age with chronic (≥1 year duration) nonischemic cardiomyopathy (NISCM), New York Heart Association (NYHA) functional class II-III symptoms on stable medical therapy (≥3 months of stable doses of β-blocker, angiotensin inhibitor or receptor blocker, and aldosterone inhibitor \[if appropriate\] therapies) with a documented left ventricular (LV) ejection fraction ≤40% and evidence of LV dilation will be eligible for study participation.~* The diagnosis of a nonischemic etiology for the cardiomyopathy must be supported by coronary angiography, stress echocardiography, or nuclear scintigraphy.~* To allow for a comparison of treatment effect in diabetic versus nondiabetic NISCM, half (n=20) of the subjects enrolled will be diabetic~Exclusion Criteria:~* Subjects with HF that is deemed to be ischemic, congenital, valvular, or infiltrative in etiology, or chemotherapy/toxin-induced will not be eligible for enrollment.~* Other exclusion criteria include the presence of a life-threatening illness with a projected survival ≤6 months;~* recurrent ventricular arrhythmias; end-stage renal failure;~* ongoing infection;~* inability to follow-up;~* collagen vascular disease (lupus, sarcoid);~* enrollment in another investigational study;~* unstable or symptomatic peripheral artery disease;~* prior or active Zn supplementation;~* or ongoing alcohol abuse.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CHF patients Given Zinc Acetate (Type: EXPERIMENTAL): Patients with CHF received zinc acetate 50 mg po TID. This is a pre-post study
- Healthy controls (Type: NO_INTERVENTION): Health controls; no zinc acetate administered.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: D-0316 First Time in Patients Ascending Dose Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses~* Histological or cytological confirmation diagnosis of Non Small Cell Lung Cancer (NSCLC).~* Radiological documentation of disease progression while on a previous continuous treatment with an EGFR TKI e.g. gefitinib or erlotinib. In addition other lines of therapy may have been given. All patients must have documented radiological progression on the last treatment administered prior to enrolling in the study.~* Confirmation that the tumour harbours an EGFR T790M mutation.~* No deterioration over the previous 2 weeks and minimum life expectancy of 12 weeks.~* Evaluable or measurable disease per RECIST v1.1~Exclusion Criteria:~* Treatment with an EGFR TKI (erlotinib or gefitinib) within 14 days of the first dose of study treatment.~* Any cytotoxic chemotherapy, investigational agents or other anticancer drugs from the treatment of advanced NSCLC from a previous treatment regimen or clinical study within 14 days of the first dose of study treatment.~Other protocol defined inclusion/exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Daily oral dose of D-0316 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: New Therapeutical Perspectives in Cases of Phonological Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Parents/guardians and child agree to participate and have signed the Informed Consent Form;~* Have age between 4:0 to 8:11 (years:months);~* Present diagnosis of phonological disorders;~* Present hearing thresholds within the normal range~Exclusion Criteria:~* Present neurological impairment, emotional and/or cognitive clearly diagnosed, or have complaint;~* Present any degree of hearing loss is the type conductive, mixed or sensorineural, and middle ear disorders in time of selection, as well as having presented otitis complaints;~* Present language impairment associated with speech sound disorder;~* Present commitment in the stomatognathic system that can interfere in the speech production;~* Have been received speech and language therapy before.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 9 Years
- Healthy Volunteers: t

Study Arms:
- Traditional Phonological Therapy (Type: ACTIVE_COMPARATOR): This intervention will be intermediated by the traditional model cycles. This approach has the principle of treating the suppression of operant phonological processes in child's speech, from the awareness of sound-target characteristics operating in that phonological process.
- Software Phonological Therapy- SIFALA (Type: EXPERIMENTAL): This intervention will be intermediated by the software SIFALA. The software SIFALA, allows to select target segments using the Modelo de Estratos (second model Strata), based on the level segment of production and complexity of distinctive features, from the child's sound system analysis and planned generalizations. It also seeks the treatment of phonological disorders, by selection stimulus words in more favorable environments and playful activities with computer resource for the correct production of the target segment in the words stimulus, promoting the spread segments.
- Placebo Therapy (Type: PLACEBO_COMPARATOR): No interventional group. This group will be the sham group. The proposed activities will be fun games on the computer, there is no relationship with speech and it will be not emphasized the correct sound production, will only play activities.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The subject has a clinical diagnosis of type 1 diabetes mellitus requiring treatment with insulin for a minimum of 6 months at Screening; -OR- The subject has a clinical diagnosis of type 2 diabetes requiring treatment with insulin with or without oral antidiabetic agents for a minimum of 6 months at Screening.~* The subject has a HbA1c of 7.0% to 11.0% at Screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pramlintide (Type: EXPERIMENTAL): Pramlintide acetate injection is a clear, colorless, sterile solution for SC injection.~It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43-mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete